Advertisement
Canada markets open in 3 hours 47 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7325
    +0.0002 (+0.02%)
     

  • CRUDE OIL

    83.80
    +0.23 (+0.28%)
     

  • Bitcoin CAD

    88,038.64
    +780.53 (+0.89%)
     

  • CMC Crypto 200

    1,391.10
    -5.44 (-0.39%)
     

  • GOLD FUTURES

    2,361.30
    +18.80 (+0.80%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,718.50
    +151.00 (+0.86%)
     

  • VOLATILITY

    15.68
    +0.31 (+2.02%)
     

  • FTSE

    8,110.40
    +31.54 (+0.39%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6822
    +0.0001 (+0.01%)
     

Why Mersana Therapeutics (MRSN) Could Be Positioned for a Surge

Zacks Equity Research
·2 min read

Mersana Therapeutics, Inc., MRSN is a clinical-stage biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on MRSN’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Mersana Therapeutics could be a solid choice for investors.

Current Quarter Estimates for MRSN

In the past 30 days, four estimates have gone higher for Mersana Therapeutics while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 38 cents a share 30 days ago, to a loss of 30 cents today, a move of 21.1%.

ADVERTISEMENT

Current Year Estimates for MRSN

Meanwhile, Mersana Therapeutics’s current year figures are also looking quite promising, with five estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $1.48 per share 30 days ago to a loss of $1.27 per share today, an increase of 14.2%.

Mersana Therapeutics, Inc. Price and Consensus

Mersana Therapeutics, Inc. Price and Consensus
Mersana Therapeutics, Inc. Price and Consensus

Mersana Therapeutics, Inc. price-consensus-chart | Mersana Therapeutics, Inc. Quote

Bottom Line

The stock has also started to move higher lately, adding 139.8% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

These Stocks Are Poised to Soar Past the Pandemic

The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.

Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.

See the 5 high-tech stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Mersana Therapeutics, Inc. (MRSN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research